temsirolimus + cisplatin + erlotinib

A three-drug investigational oncology combination pairing the mTOR inhibitor temsirolimus, the DNA-damaging platinum agent cisplatin, and the EGFR tyrosine kinase inhibitor erlotinib. The regimen was explored in a single-institution phase I dose-escalation study in advanced solid tumors, motivated by preclinical rationale that simultaneous inhibition of EGFR signaling and mTOR can overcome resistance driven by PI3K/AKT/mTOR activation, while cisplatin adds cytotoxic DNA damage, with particular interest in triple-negative breast cancer biology involving PTEN loss, EGFR expression, and p53 mutation. In early results, a de-escalated dose level of cisplatin 30 mg/m2 (days 1 and 8 of 21-day cycles), temsirolimus 15 mg IV (days 1 and 8), and erlotinib 75 mg PO daily was reported as tolerable after initial DLTs at higher erlotinib dose; a short-lived partial response was observed in a TNBC patient, and common toxicities included thrombocytopenia and expected class effects like rash, mucositis, diarrhea, and renal/electrolyte abnormalities. Prophylactic doxycycline was used to mitigate EGFR-inhibitor rash in this trial context.[1][3]

Other names

temsirolimus plus cisplatin plus erlotinib